RUNX3 regulates the susceptibility against EGFR-targeted non-small cell lung cancer therapy using ⁴⁷Sc-conjugated cetuximab.

ABSTRACT:

Background

Radioimmunotherapy with cetuximab and conjugates with various radioisotopes is a feasible treatment option for different tumor models. Scandium-47 (⁴⁷Sc), one of several β^--particle-emitting radioisotopes, displays favorable physical and chemical properties for conjugation to monoclonal antibodies. However, the therapeutic efficacy of ⁴⁷Sc in preclinical and clinical studies is largely unknown. Given that intrinsic alterations in tumors greatly contribute to resistance to anti-epidermal growth factor receptor (EGFR)-targeted therapy, research on overcoming resistance to radioimmunotherapy using cetuximab is required.

Methods

⁴⁷Sc was produced by irradiation of a CaCO₃ target at the HANARO research reactor in K

SUBMITTER: Kim DM 

PROVIDER: S-EPMC10337176 | biostudies-literature | 2023 Jul

REPOSITORIES: biostudies-literature